Neptune to Hold Conference Call
2012年10月22日 - 9:00PM
Neptune Technologies & Bioressources Inc.
("
Neptune") (Nasdaq:NEPT) (TSX:NTB) will be
holding a conference call on
Tuesday October 23, 2012 at
4:30 ET. The call will focus solely on the presentation of
the financial results.
The conference call host will be Henri Harland, President &
CEO.
To access the conference call by phone within Canada & the
U.S., the toll‐free number is
1‐877-380-5664
Outside Canada and the U.S., dial
1‐631-813-4882
Conference call details:
Conference Topic: Neptune Technologies & Bioressources
Second Quarter 2012 Earnings Call
Conference ID: 54141801
Management will accept questions related to the financial
results by telephone during the Q&A period at the end of the
presentation. Questions can also be forwarded in advance or during
the presentation to f.harland@neptunebiotech.com.
An archived recording of the webcast will be available on
Neptune's website (www.neptunebiotech.com) two hours after the
webcast.
The unaudited interim consolidated financial statements of
Neptune as at and for the interim period ended August 31, 2012 and
related MD&A are available on SEDAR at www.sedar.com, on EDGAR
at www.sec.gov/edgar.shtml and on Neptune's website at
http://www.neptunebiotech.com.
About Neptune Technologies & Bioressources
Inc.
Neptune is a biotechnology company engaged primarily in the
development, manufacture and commercialization of marine-derived
omega-3 polyunsaturated fatty acids ("PUFAs").
Neptune produces omega-3 PUFAs through its patented process of
extracting oils from Antarctic krill, which omega-3 PUFAs are then
principally sold as bulk oil to Neptune's distributors who
commercialize them under their private label primarily in the U.S.,
European and Australian nutraceutical markets. Neptune's lead
products, Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™),
generally come in capsule form and serve as a dietary supplement to
consumers.
Through its subsidiaries Acasti Pharma Inc.
("Acasti") (TSX-V:APO) and NeuroBio, in which
Neptune respectively holds 57% and 99% of the voting rights,
Neptune is also pursuing opportunities in the medical food and
prescription drug markets. Acasti and NeuroBio respectively focus
on the research and development of safe and therapeutically
effective compounds for highly prevalent atherosclerotic
conditions, such as cardiometabolic disorders and cardiovascular
diseases, and for neurodegenerative and inflammation related
conditions. Acasti's lead prescription drug candidate is CaPre®, a
purified high omega-3 phospholipid concentrate derived from Neptune
krill oil being developed to address the prevention and treatment
of cardiometabolic disorders, including hypertriglyceridemia, which
is characterized by abnormally high levels of triglycerides.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024